Director Nacho Guzman captures the beauty and versatility of lighting
Check out more of Guzman’s work here: www.hazefilms.com
Listen to more of Opale’s music here:
Director Nacho Guzman captures the beauty and versatility of lighting
Check out more of Guzman’s work here: www.hazefilms.com
Listen to more of Opale’s music here:
Annette Guzman-Torres was feeling discouraged and frustrated, her anxiety fueled by the uncertainty of a bleak job market during the coronavirus pandemic. The 44-year-old married mother of two boys is close to finishing the capstone project for her doctorate from Capella University. “I was like, I have no job, nowhere to go, nothing to do,” said the resident of Bloomfield, New Jersey.
Britain's test and trace system needs to be improved, transport minister Grant Shapps said on Tuesday, adding that the government had no choice but spend a lot of money on it during the coronavirus crisis. "We have to get through this coronavirus and I'm afraid there has been no other option but to spend a lot of money," Shapps told Sky News. "We've said that we want test and trace to be a lot better."
Black Friday iRobot Roomba deals for 2020, including Roomba s9, s9+, i7, 980 & more robovac deals
The government has announced a maximum of 4,000 fans will be allowed in low-risk areas.
Follow the latest updates
ANNOUNCEMENT NO. 101 - 24 NOVEMBER 2020In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90.Kind regards,Dampskibsselskabet NORDEN A/SMartin BadstedCFOFor further information:Martin Badsted, CFO, tel.: +45 3315 0451Attachments * No. 101 Managers' transactions * Transactions by persons discharging managerial responsibilities and persons
Lionel Messi might be a Manchester man after all.
Directors had set up rescue refinancing but investors demand better deal
Save on a selection of Dyson cordless vacuum deals at the Black Friday sale, featuring all the latest Cyclone V10 and V11 Animal offers
On 20 November, the news conference for the 2020 Zhuhai International Design Week & Beijing International Design Week – Zhuhai (hereinafter referred to as "2020 Zhuhai International Design Week") was held at Zhuhai International Convention & Exhibition Center. The Zhuhai International Design Week is co-organized by Zhuhai Huafa Group, Beijing Gehua Group, Hong Kong Federation of Design Association and Macau Design Center under the guidance of Zhuhai Municipal People's Government. The theme for the event is "Beautiful City & Big Health", with key activities taking place between December 4-6 at Zhuhai International Convention & Exhibition Center.
The bridge had been closed for nearly two years for a rehab project.
Children in crisis: Councils an ‘invisible crisis’ played out during lockdown as social workers warn surge in domestic violence, alcohol abuse and anxiety has put caseloads at an all-time high
(Bloomberg) -- Germany’s DAX benchmark is about to undergo the biggest makeover since its inception in 1988.Index operator Qontigo, a unit of Frankfurt-based Deutsche Boerse AG, plans to increase the number of members to 40 from 30 and impose new quality criteria on both existing and prospective members.New rules require members to post quarterly statements, as well as audited annual results, with a fast exit for those failing to present them on time. Supervisory boards must have staffed audit committees. Effective immediately, aspiring members will need to show they’ve been profitable for two years to join the benchmark. The changes follow a four-week long market consultation that got more than 600 responses.“Market participants will benefit from a simple set of rules in line with international standards and new qualification criteria for the German benchmark index,” Stephan Flaegel, Global Head of Benchmarks & Indices at Qontigo, said in a statement.While the DAX’s composition was long governed by rankings based on market cap and traded volume, the index owner plans to drop the volume ranking, leaving market cap, a general liquidity threshold and the new qualitative criteria as the main tests for entry.The earnings reporting requirements will become effective during the first-quarter index review, while the increase to 40 members will only take effect in the third quarter next year. Existing members that don’t yet have an audit committee will get until August 2022 to adapt to the new rule.The only proposal that was not adopted would have banned companies involved in “controversial weapons;” according to Qontigo, this would have affected one current member of the MDAX.The push to reform index rules, which had remained mostly unchanged for the past three decades, was sparked by the high-profile case of Wirecard AG, the fraudulent fintech that was a DAX member for two years despite repeated allegations of accounting irregularities. When it collapsed in June, pressure to overhaul the index mounted as existing rules didn’t allow for the benchmark’s first-ever insolvent member to be ejected right away.Delivery Hero SE joined the DAX to replace Wirecard, and some investors expressed unease about the fact that the Berlin food delivery firm had never reported an annual profit. Had the new rules already been in place, it would not have been eligible to join.Inclusion in benchmark indexes is becoming more important for companies in a financial landscape increasingly dominated by passive investment funds. Bank of America Corp. strategists predict that equity assets in index-tracking funds will surpass actively managed portfolios in August 2021. About 14 billion euro in exchange traded funds track Germany’s DAX Index, data compiled by Bloomberg shows.(Adds details on timeline of changes, index operator comment.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Save on Dyson deals at the Black Friday 2020 sale, including Dyson cooling fans, cordless vacuum cleaners & purifier offers
AO World revenues have soared by more than 50%, with the online retailer’s boss declaring the first half has been “like no other”. The FTSE 250 company, led by John Roberts, saw high demand for products online in a period that saw swathes of high street retailers have to close for Covid-19 lockdowns.
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering. The 'Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 - 2030' report features an extensive study of the current market landscape and future opportunities for the contract service providers focused on drugs and drug delivery systems. It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in this domain. Targeting the delivery of drugs directly into the lungs is deemed to be the most effective way to ensure optimal therapeutic benefits while treating pulmonary disorders. In addition, this route of administration has also been shown to be effective for drugs intended to treat a variety of other conditions, including various metabolic (460+ million adults estimated to be living with diabetes) , hormonal, autoimmune, infectious diseases/disorders and mental health conditions (260 million individuals estimated to be suffering from depression and around 50 million have epilepsy, worldwide). As a result, innovators in the pharmaceutical industry are engaged in efforts to develop the means to formulate and administer pharmacological interventions via inhalation and/or the intranasal route. Since 2019, the FDA has approved multiple inhaled and intranasal drug products, namely TOSYMRAT (migraine), NUMBRINOT (local anesthetic), GIMOTIT (diabetic gastroparesis), VALTOCO (epilepsy), NAYZILAM (epilepsy), DUAKLIR PRESSAIR (COPD), PROAIR DIGIHALERT (asthma and COPD), AIRDUO DIGIHALERT (asthma), SPRAVATO (depression). Presently, several players are attempting to develop inhalable versions of different classes of drugs. In such endeavors, reformulating complex therapeutic molecules (such as biologics), novel drug classes (such as nanoparticle based medicine) and those intended for systemic delivery, present unique challenges.Further, the inhaled route of delivery itself has always been associated with several challenges, mostly related to ensuring the drug to its intended target. These concerns are further compounded by multiple physiological barriers, such as mucus hypersecretion/thickening, narrowing/collapse of airways, fibrosis and poor blood circulation. In order to navigate through the aforementioned challenges, innovators prefer to rely on specialty service providers with expertise in inhaled and intranasal nasal medicine. Such players, given their experience and niche expertise, enable innovator companies to not only expedite product development and production timelines, but also offer cost saving opportunities as well. Further, such service providers generally have the necessary infrastructure to scale-up operations in order to meet the evolving needs of a business across different stages of product development. Given the anticipated growth in demand for inhaled and intranasal drug products, the specialty contract services market catering to this segment of the pharmaceutical industry, is anticipated to witness substantial growth in the coming years. Key Questions Answered * Who are the leading contract service providers offering inhalable and intranasal products related services, across the world? * In which regions are majority of the inhaled and intranasal product related manufacturing facilities located? * What percentage of inhaled and intranasal manufacturing operations are outsourced? * Which partnership models are commonly adopted by stakeholders in this industry? * What is the impact of COVID-19 outbreak on inhaled and intranasal product services market? * What is the current, global demand for inhaled and intranasal products? * How is the current and future market opportunity likely to be distributed across key market segments?Companies Mentioned * 3M * 3P innovation * Actelion Pharmaceuticals * Aerami Therapeutics (formerly Dance Biopharm) * Aerosol Research and Engineering Laboratories * Akums Drugs & Pharmaceuticals * Alcami * Alpic Biotech * Altaris Capital Partners * Altimmune * Amneal Pharmaceuticals * Aptar Pharma * Arch Biopartners * Arcturus Therapeutics * ASM Aerosol-Service * Aspen Pharmacare * AstraZeneca * Atossa Therapeutics * Aurohealth * Basic Pharma * Battelle * Bespak * Beximco Pharmaceuticals * BioCare Group * Biofilms Research Center for Biointerfaces, Malmo University * Boehringer Ingelheim * Breath Therapeutics * Capsugel * Carclo Technical Plastics * Catalent * CF PharmTech * Charles River Laboratories * Chemic Laboratories * Chiesi Farmaceutici * Chromcore Lifesciences * Cirrus Pharmaceuticals * COC Farmaceutici * Colep * Confab * Consort Medical * Contract Pharmaceuticals * Creative Biolabs * Circassia * CrystecPharma * Curida * CytoAgents * Dalton Pharma Services * DFE Pharma * Doctor Pack * Dorizoe Lifesciences * DPT Laboratories * Dr. Reddy's Laboratories * DRK Pharma Solutions * Dwarkesh Pharmaceuticals * EKG Life Science Solutions * Elfin Drugs * Emmace Consulting * Ennaid Therapeutics * Ethris * Eurofins * Evoke Pharma * Evonik * Experic * Farbe Firma * FAMAR * Focus Inhalation * Forefront Medical Technology * Forest Laboratories * Genentech * Gerresheimer * Getron Pharmaceuticals * Gilead Sciences * GlaxoSmithKline * Global Pharma * Hikma Pharmaceuticals * Horizon Pharmaceuticals * Hovione * Humanigen * Iconovo * IIT Research Institute (IITRI) * Impopharma * Importfab * Inhalexpert * InhaTarget Therapeutics * Insmed * Intas Pharmaceuticals * Intertek * Invion * iPharma * ITC Farma * J Pharmaceuticals * Jabil * Jagotec * Janssen Pharmaceuticals * Johnson & Johnson * Kiel University * Kindeva Drug Delivery * King's College London * Kymos Pharma Services * Labiana Pharmaceuticals * Lamda Laboratories * Lannet Technologies * LEAX Group * Lepharm * Life Vision Healthcare * Lindal Group * Liquidia Technologies * Lomapharm * Lonza * Lovelace Biomedical * Lxir Medilabs (A unit of SMM Life Sciences) * M2M Pharmaceuticals * Macter International * Malmo University * MannKind * Mapaex * Maya Biotech * McMaster University * Medicair Bioscience Laboratories * Medicilon * Medlab Pharmaceuticals * MedPharm * Menarini Group * Merck * Micro-Sphere * MidasCare * Mipharm * MMG Healthcare * Moderna Therapeutics * Molex * Medicon Valley Inhalation Consortium (MVIC) * Mylan * Nanologica * Nanopharm * Napp Pharmaceuticals * Nelipak Healthcare Packaging * Nelson Laboratories * Nemera * Nephron Pharmaceuticals * Neurelis * Neurimmune * Newtec Pro Manufacturing * Next Breath * Nipro * Nitto Medic * Nivon Specialties * Noble * Novartis * One Pharma * Orion * Ote Pharma * Optinose * Paragon Nordic * PARI Pharma * PCI Pharma Services * Penta Arzneimittel * Pfizer * Pharma Stulln * Pharma Tech * PharmaCielo * Pharmaserve * Pharmaterials * PHAST (Acquired by Eurofins) * Phillips-Medisize * Pine Lake Laboratories * Polyphor * PPD Laboratories * Probiotec * Propeller Health * Proveris Scientific * Pulmatrix * PulmoFlow * Pursuit Pharma * Pushkar Pharma * Quotient Sciences * Recipharm * Renaissance Pharmaceuticals * Roche * Rommelag * Rubicon Research * S.R.Chemicals and Pharmaceuticals * SAFE Pharmaceutical * Salvat * Sandoz * Sanofi * Sciarra Laboratories * Seikagaku * Sentiss Pharma * Servier Pharmaceuticals * SHL Group * Simpler Consulting * SkyePharma * Smithers * Spicona * Stabicon Life Sciences * Stevanato Group * Summit Biosciences * Sunovion * Sunovion Pharmaceuticals * Synerlab * Takeda * Teva Pharmaceuticals * The Indian Pharmaceutical Association * The Ritedose Corporation * Theravance Biopharma * Tinuum * Toxikon * Trillium Health Care Products * UCB Pharma * Ultratech India * United Therapeutics * University of Birmingham * University of Copenhagen * University of Cyprus * University of Florida * University of Turku * Bausch Health (formerly Valeant Pharmaceuticals) * Vectura * ViralClear Pharmaceuticals (A subsidiary of BioSig Technologies) * Vinventions * Vivimed * West Coast Pharmaceutical * Westmed Medical Group For more information about this report visit https://www.researchandmarkets.com/r/onk748Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
When Marina Gómez and her fellow mortuary worker enter a room at a nursing home to remove the body of a COVID-19 victim, they work methodically and in silence. A sort of wartime atmosphere had brought people together in solidarity amid the misery.
Thai police will deploy nearly 6,000 officers on Wednesday for a demonstration at the office that manages the royal fortune by protesters demanding that King Maha Vajiralongkorn give up personal control of the assets. Police said on Tuesday that no protesters would be allowed within 150 metres (450 feet) of the Crown Property Bureau, where royalists have also said they plan to gather in defence of a monarchy that faces its biggest challenge in decades. "Depending on how protesters behave, we will take appropriate measures," he told a news conference.
China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") has established strategic cooperation with three top institutions on November 23 in Beijing, China, to take lead in a joint research on the energy and chemical industry's carbon emissions peak and carbon neutral.
Unaudited Results for the six months ended 30 September 2020Corporate and Operational UpdateTORONTO, ON / ACCESSWIRE / November 24, 2020 / Eco (Atlantic) Oil & Gas Ltd.